Zestra in Women With Mixed Sexual Dysfunction

July 4, 2007 updated by: QualiLife Pharmaceuticals

A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Trial of the Efficacy and Safety of Zestra(TM) in Women With Mixed Desire/Interest/Arousal/Orgasm Disorders

The objective of this study is to evaluate the clinical efficacy and safety of Zestra(TM) in women with acquired mixed desire/interest/arousal/orgasm disorders under conditions of home usage. The primary efficacy hypothesis will compare the effect of Zestra versus placebo on the incidence of "successful and satisfactory" sexual encounters.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

This Phase 3 study is being conducted to evaluate the efficacy and safety of Zestra(TM) compared to a placebo oil in women diagnosed as having acquired mixed interest/desire/arousal/orgasm disorders with varying presentations of each component in conditions of home use in conjunction with sexual activities. The study is a randomized, placebo-controlled, double-blind, parallel design trial. After subject screening, there is an open-label, placebo run-in period of four weeks, followed by a double-blinded 12 week treatment period. This design is consistent with the Paris 2003 recommendations for female sexual dysfunction (FSD) clinical trials and the Food and Drug Administration (FDA) Guidance on Clinical Development of Products for the Treatment of Female Sexual Dysfunction although the duration of active treatment in this study is 12 weeks rather than the 6 months suggested by the FDA for Phase 3 studies.

Primary efficacy assessment will be the subjects' assessments of "successful and satisfactory" sexual encounters as recorded in a diary (question 10 in the Female Sexual Encounter Profile [FSEP©]). Secondary evaluations of efficacy will include the other FSEP questions, a subject self-assessment questionnaire (Female Sexual Function Index [FSFI©]), two global assessment questions, a treatment satisfaction questionnaire (WITS©), the Beck Depression Inventory, the Dyadic Adjustment Scale (DAS), a consumer testing survey (QualiLife Consumer Testing Survey [QCTS©]), and a distress scale (Female Sexual Distress Scale [FSDS©]), sexual encounter frequency, and drop-out rates.

The selection of outcome measures in this study is based on the most current information available. The FSEP© has been used in many FSD studies and specifically meets the FDA recommendations for a primary outcome measure. The initial validation study of the FSEP© was presented at the 11th World Congress of the International Society for Sexual and Impotence Research in Buenos Aires in 2004. The FSFI©, the FSDS©, and global assessment questions are routinely used in FSD trials, and the first two have been subjects of ongoing validation for a number of years. Global assessment questions have historically been used to calculate response rates. The QCTS© is a consumer testing survey which addresses issues ultimately impinging on product marketability. WITS© is a female oriented treatment satisfaction instrument newly developed by Stanley E. Althof, Ph.D., Eric W. Corty, Ph.D., and Miki Wieder, M.A., 2004; the authors' authorized use of this instrument in this study is part of the ongoing validation for this questionnaire. Since depression can contribute to FSD and FSD can contribute to depression, seriously confounding diagnostic and treatment schema, the commonly used Beck Depression Inventory will be administered at the end of the baseline run-in period and then at the end of the double-blinded treatment period. Relational factors have the same confounding issues as depression; thus, the participants' attitudes about their relationships with their partners will be assessed at baseline and end of treatment using the Dyadic Adjustment Scale. Sexual encounter frequency may prove a useful outcome measure since a beneficial effect of treatment may be reinforcing, while lack of efficacy by the placebo may be discouraging. A similar hypothesis is the basis of drop-out analysis.

Study Type

Interventional

Enrollment

200

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • United States
    • California
      • Tarzana, California, United States, 91356
        • West Coast Clinical Research
    • Colorado
      • Aurora, Colorado, United States, 80012
        • Urology Research Options
    • Florida
      • Aventura, Florida, United States, 33180
        • South Florida Medical Research
      • West Palm Beach, Florida, United States, 33401
        • Center For Marital and Sexual Health of South Florida
    • Indiana
      • Fort Wayne, Indiana, United States, 46825
        • Northeast Indiana Research
      • Indianapolis, Indiana, United States, 46206-5250
        • Outpatient Clinical Research Facility
    • Massachusetts
      • Peabody, Massachusetts, United States, 01960
        • Lahey Clinic
    • New York
      • Garden City, New York, United States, 11530
        • AccuMed Research Associates
      • Poughkeepsie, New York, United States, 12601
        • Hudson Valley Urology, PC
    • Ohio
      • Cleveland, Ohio, United States, 44109
        • MetroHealth Medical Center
    • Pennsylvania
      • Philadelphia, Pennsylvania, United States, 19146
        • The Pelvic and Sexual Health Institute
    • Texas
      • San Antonio, Texas, United States, 78229
        • Urology San Antonio Research, PA
    • Wisconsin
      • Milwaukee, Wisconsin, United States, 53209
        • Midwest Research Specialists, LLC

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

21 years to 65 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Females 21 to 65 years of age.
  • Have been previously "functional" or experienced sexual desire/arousal/orgasm for several years in the past.
  • Postmenopausal (no menses for one year and appropriate elevation of follicle stimulating hormone [FSH]), or using hormonal contraception for at least 3 months prior to study entry, or have had a tubal ligation at least 3 months prior to study entry or confining all sexual intercourse to a vasectomized partner.
  • Provide written informed consent.
  • Have a stable heterosexual relationship with a male partner for at least 1 year. Partner must attend screening visit and also sign a separate informed consent form.
  • Have a partner score of "not impotent" or "minimally impotent" on the Single Question Assessment of Erectile Dysfunction. The subject will determine the partner score privately.
  • Willing to engage in sexual activities with intent to attain orgasm at least 2 times per week.

  • Meet the diagnostic criteria for one or more of the following acquired disorders:

    • Women's sexual interest/desire disorder;
    • Subjective sexual arousal disorder;
    • Combined genital and subjective arousal disorder;
    • Genital sexual arousal disorder;
    • Women's orgasmic disorder.
  • Have a score of > 15 on the FSDS .
  • Willing and able to understand and comply with all study requirements.

Exclusion Criteria:

  • Evidence of unresolved sexual trauma or abuse.
  • Primary anorgasmia, vaginismus, sexual pain disorder, sexual aversion disorder, or persistent sexual arousal disorder.
  • Female sexual dysfunction caused by untreated endocrine disease, e.g., hypopituitarism, hypothyroidism, diabetes mellitus.
  • Pregnant or nursing.
  • Sensitivity to any of the ingredients in Zestra for Women(TM).
  • Chronic or complicated urinary tract or vaginal infections within previous 12 months.
  • Pelvic inflammatory disease within previous 12 months.
  • Currently active sexually transmitted disease.
  • Chronic dyspareunia not attributable to vaginal dryness within previous 12 months.
  • Currently active moderate to severe vaginitis.
  • Cervical dysplasia within previous 12 months.
  • Significant cervicitis as manifested by mucopurulent discharge from the cervix.
  • Significant gynecologic conditions such as uterine fibroids, vulvar vestibulitis, or vaginismus that may (in the investigator's opinion) interfere with the subject's ability to comply with study procedures.
  • Psychoses and bipolar disorder.
  • Use of neuroleptics or lithium within previous 3 months.
  • Unwillingness to forego any medications, herbal treatments, or dietary supplements intended to enhance sexual function during the course of the study.
  • History of myocardial infarction within previous 6 months.
  • History or evidence of significant renal or hepatic disease within previous 6 months.
  • Significant central nervous system diseases within the last 6 months, i.e., stroke, spinal cord injury, multiple sclerosis, etc.
  • Unwillingness to omit cunnilingus from sexual activities during the study. No post-coital fellatio allowed.
  • Any condition which, in the Investigator's opinion, would interfere with the subject's ability to provide informed consent, to comply with study instructions, or which might confound the interpretation of the study results.
  • Any condition which would endanger the participant if she participated in this trial.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Safety: adverse events, physical examinations, clinical laboratory evaluations
Female Sexual Function Index domain scores and totals
Time Frame: Baseline to Visit 6 (12 weeks)
Baseline to Visit 6 (12 weeks)

Secondary Outcome Measures

Outcome Measure
Efficacy: incidences for remaining FSEP© questions, FSFI© (all domains), FSDS©, global assessment questions, WITS©, QCTS©, Beck Depression Inventory, Dyadic Adjustment Scale, sexual encounter frequency, drop out rates

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

QualiLife Pharmaceuticals

Investigators

  • Study Director: David M Ferguson, PhD, MD, FACCP, Clinical Research Services Consulting
  • Principal Investigator: Julia R Heiman, PhD, Kinsey Institute for Research in Sex, Gender and Reproduction

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

March 1, 2006

Study Completion

March 1, 2007

Study Registration Dates

First Submitted

June 30, 2005

First Submitted That Met QC Criteria

July 8, 2005

First Posted (Estimate)

July 11, 2005

Study Record Updates

Last Update Posted (Estimate)

July 6, 2007

Last Update Submitted That Met QC Criteria

July 4, 2007

Last Verified

July 1, 2007

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • Z-04

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Sexual Dysfunction, Psychological

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Poland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe